Exelixis licenses AI-designed cancer drug from Insilico Medicine
Outsourcing Pharma
SEPTEMBER 14, 2023
Insilico Medicine is due to receive $80 million upfront plus potential milestone payments as Exelixis gains global rights to develop and commercialize the Hong Kong firmâs small molecule cancer treatment.
Let's personalize your content